Prospective, Open-Label, Multi-Center, Randomized Study to Compare the Effectiveness, Safety, and Tolerability of Lulican Shampoo Versus Ketoconazole Shampoo in Indian Adult Patients With Mild to Moderate Scalp Seborrheic Dermatitis (LEAD Study)

The study compared the effectiveness, safety, and tolerability of Lulican™ shampoo and Ketoconazole shampoo in treating mild to moderate scalp seborrheic dermatitis in Indian adults. Conducted over four weeks, the study found that Lulican™ resulted in a 68% reduction in the Seborrheic-Dermatitis-Severity-Score (SDSS) compared to 57.9% with Ketoconazole. Additionally, 58% of patients using Lulican™ achieved excellent to moderate responses, versus 44% with Ketoconazole. Both treatments were well tolerated, but Lulican™ showed significantly better product tolerability and cosmetic acceptability. Quality of life, measured by the Scalpdex-23 score, improved by 35.7% with Lulican™ compared to 21.1% with Ketoconazole. The study concluded that Lulican™ is a preferred treatment option due to its superior improvement in quality of life.